2013 - ISODP 2013 Congress


Oral Presentation 8 on Living Donation

15.2 - Use of Kidneys with Small Renal Tumors for Transplantation: Potential benefits of organ recycling for high-risk dialysis patients

Presenter: Yoshihide, Ogawa, Akishima, Japan
Authors: Yoshihide Ogawa, Keimei Kojima, Rensuke Mannami, Makoto Mannami, Keiichi Kitajima, Mitsuo Nishi, Hisaaki Afuso, Seiichi Ito, Naoki Mituhata


Use of Kidneys with Small Renal Tumors for Transplantation: Potential benefits of organ recycling for high-risk dialysis patients

Yoshihide Ogawa1, Keimei Kojima2, Rensuke Mannami2, Makoto Mannami2, Keiichi Kitajima3, Mitsuo Nishi4, Hisaaki Afuso5, Seiichi Ito6, Naoki Mituhata6

1Urology, Tokyo-West Tokushukai Hospital, Akishima, Japan, 2Urology, Uwajima Tokushukai Hospital, Uwajima, Japan, 3Urology, Kagoshima Tokushukai Hospital, Kagoshima, Japan, 4Urology, Saint Martin's Hospital, Sakaide, Japan, 5Urology, Chubu Tokushukai Hospital, Okinawa, Japan, 6Urology, Kure Kyosai, Kure, Japan

OBJECTIVES:  Buell, Mannami, Nicol, Masquera, and He respectively reported 14, 8, 31, 7, and 19 transplant cases using kidneys after resection of RCC. Donor-transmitted renal cell carcinoma in transplant is unavoidable but guidelines were issued to optimize organ usage. To balance the risk of dying on dialysis against cancer transmission, high-risk recipients are suggested best to deserve the procedure. Utilizing these discarded kidneys may help to suppress the rise of organ trafficking and transplant tourism. Therefore, we performed a prospective open trial that utilizes resected kidneys for transplant into third-party recipients after restoration.

SUBJECTS and METHODS:  Our clinical trial (stage 1 and 2) consisted of 5 cases each has been completed after one year of follow-up.  Donors were recruited from 6 donor-harvesting hospitals and subsequently selected from among patients who opted to undergo nephrectomy for small RCC (< 4 cm) after extensive discussion of other treatment modalities. The recipient selection was mainly based on ABO compatibility and clinical scores, and immunological data (PRA and HLA mismatch) were added to the selection criteria in the extended trial (stage 2).

RESULTS:  In the stages1 and 2, five male patients and 3 male & 2 female patients were the donors with T1a RCC, respectively. The nephrometry RENAL scores for their renal tumors were of low and moderate complexity. A total of 56 dialysis patients and 76 patients were enrolled as candidate recipients for the stages 1 and 2, respectively. Five recipients aged 47-66 and 46-65 years were selected in either stage 1 or 2, respectively. Two recipients had a history of kidney transplant in each stage. Four recipients in each stage have experienced rejection so far and the latest serum creatinine levels range from 1.10 to 5.55 mg/dl without recurrence of RCC after 17 to 43 months of follow-up.

CONCLUSIONS:  Restored kidney transplant led to achieving good renal function without recurrence of RCC at 17-43 months. The procedure appears technically demanding, however, with expertise hands selected candidates can benefit from accepting these discarded kidneys. 


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi